Business
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9
About this update from Rigel Pharmaceuticals, Inc.
[{"type":"text","content":"Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9 millionREZLIDHIA U.S. commercial launch continues to progress and is supported by recent addition to NCCN Guidelines® for AMLConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., March 7, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2022, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and sales of REZLIDHIA™ (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.\n\"2022 was a year of significant accomplishments for Rigel, as we expanded our commercial hematology-oncology portfolio with the approval and launch of REZLIDHIA, an important new treatment option for AML patients. We also continued to strengthen our commercial execution, with TAVALISSE net product sales reaching a record high in the fourth quarter,\" said Raul Rodriguez, Rigel's president and CEO. \"We are focused on continuing the successful launch of REZLIDHIA in R/R AML, driving sales growth for TAVALISSE in ITP, and advancing our development programs. In 2023, we look forward to further expanding our hematology-oncology portfolio and clinical pipeline.\"\nBusiness Update\nIn the fourth quarter of 2022, a total of 2,417 bottles of TAVALISSE were sold in the U.S., 2,196 of which were shipped directly to patients and clinics, representing the highest number of daily bottles shipped to patients and clinics in a quarter since launch. For the full year ended December 31, 2022, 8,112 bottles of TAVALISSE were shipped directly to patients and clinics, representing an increase of 20% compared to 2021.On December 1, 2022, REZLIDHIA was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. From December 22, 2022, when REZLIDHIA became co...